drugset / Trial / NCT05634577

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

NCT05634577

Phase 2 Terminated 3 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if adding pembrolizumab to mitotane can help to control ACC. The safety of this drug combination will also be studied.

Timeline

Start
2023-03-23
Primary completion
2024-07-10
Completion
2024-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitotane Small molecule Oral
Subject Pembrolizumab Monoclonal antibody Intravenous